{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:04:48Z","timestamp":1789538688983,"version":"build-2803163510"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hailey\u2013Hailey disease (HHD), also known as benign familial pemphigus, is a rare autosomal dominant genodermatosis characterized by recurrent erosive lesions in intertriginous areas. Previous case reports have described clinical improvement with upadacitinib, but post-response maintenance strategies remain poorly defined. We report a 62-year-old woman with a 7-year history of refractory HHD who showed marked improvement after 2 months of upadacitinib 15 mg once daily. After 6 months of daily treatment, the lesions had completely cleared and disease control was stable. The regimen was then changed to 15 mg every other day after discussion with the patient. The change was based on sustained clinical control, concern about the financial burden of continued daily treatment, and a preference to limit prolonged systemic exposure; it was not prompted by an adverse event. The patient adhered to the alternate-day schedule, did not resume daily treatment, and required no rescue or additional therapy. During the subsequent 3 months, no new or recurrent lesions were observed and no apparent adverse events occurred. This case therefore documents short-term disease control after transition to an alternate-day maintenance schedule. Given the relapsing and fluctuating course of HHD and the limited follow-up after dose reduction, the observation should not be interpreted as evidence of durable remission or long-term efficacy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1935043","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:31:55Z","timestamp":1789536715000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Short-term disease control with alternate-day maintenance upadacitinib in refractory Hailey\u2013Hailey disease: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Deping","family":"Luo","sequence":"first","affiliation":[{"name":"The Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexin","family":"Zhao","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liancheng","family":"Guan","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/71701","article-title":"Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease","volume":"24","author":"Hu","year":"2000","journal-title":"Nat Genet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/9.7.1131","article-title":"Hailey-Hailey disease is caused by mutations in ATP2C1 encoding a novel Ca2+ pump","volume":"9","author":"Sudbrak","year":"2000","journal-title":"Hum Mol Genet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19583","article-title":"Patients' perspective, quality of life and treatment goals in Hailey-Hailey disease: Lessons learned from the German National Registry","volume":"38","author":"Rogner","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.25259\/ijdvl_906_2024","article-title":"Therapeutic agents for Hailey-Hailey disease: A narrative review","volume":"91","author":"Sardana","year":"2025","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.jid.2020.12.026","article-title":"SMOC1 and IL-4 and IL-13 cytokines interfere with Ca2+ mobilization in primary human keratinocytes","volume":"141","author":"Lyubchenko","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1676459","article-title":"Upadacitinib successfully treats Hailey-Hailey disease: a cases report and literature review","volume":"16","author":"Wu","year":"2026","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.09.011","article-title":"Refractory Hailey-Hailey disease cleared with upadacitinib","volume":"41","author":"Murphy","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2025.05.052","article-title":"Treatment of refractory Hailey-Hailey disease with oral upadacitinib and topical ruxolitinib 1.5% cream","volume":"64","author":"Alhwayek","year":"2025","journal-title":"JAAD Case Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcae149","article-title":"Treatment of Hailey\u2013Hailey disease with JAK inhibitors","volume":"117","author":"Cui","year":"2024","journal-title":"QJM"},{"key":"B10","unstructured":"Hailey-Hailey Disease\n          \n          2024"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.11.036","article-title":"Late-onset Hailey-Hailey disease with a novel ATP2C1 mutation in an older female patient","volume":"50","author":"Horikawa","year":"2024","journal-title":"JAAD Case Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/jcia.2024.13246","article-title":"Late-onset Hailey-Hailey disease with a novel frame-shift variant in the ATP2C1 gene","volume":"7","author":"Iwata","year":"2024","journal-title":"J Cutan Immunol Allergy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40257-019-00477-z","article-title":"Hailey-Hailey disease: An update review with a focus on treatment data","volume":"21","author":"Ben Lagha","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1155\/dth\/7369095","article-title":"Therapeutic potential of botulinum toxin in Hailey-Hailey disease","volume":"2025","author":"Rutecka-Wolak","year":"2025","journal-title":"Dermatol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf112","article-title":"Exome and transcriptome analysis link calcium channel pathway aberrations to botulinum toxin A resistance in Hailey-Hailey disease","volume":"193","author":"Yuan","year":"2025","journal-title":"Br J Dermatol"},{"key":"B16","first-page":"18","article-title":"Treatment of recalcitrant Hailey-Hailey disease with dupilumab: a case report","volume":"18","author":"Sulich-Moore","year":"2025","journal-title":"J Clin Aesthet Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.86817","article-title":"Successful treatment of hailey-hailey disease with dupilumab","volume":"17","author":"Breimann","year":"2025","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad012","article-title":"Interleukin-17A immune pattern across genetic acantholytic and blistering disorders","volume":"48","author":"Haghighi Javid","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2026.05.004","article-title":"Successful treatment of recalcitrant Hailey-Hailey disease with ixekizumab","volume":"73","author":"Bohnstedt","year":"2026","journal-title":"JAAD Case Reports"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.70343","article-title":"Effective management of recalcitrant Hailey-Hailey disease with risankizumab","volume":"65","author":"Justice","year":"2026","journal-title":"Int J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2025.09.027","article-title":"Efficacy of interleukin-12\/23 and interleukin-23 inhibitors in Hailey-Hailey disease","volume":"66","author":"Echeandia-Francis","year":"2025","journal-title":"JAAD Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_732_2025","article-title":"Successful treatment of Hailey-Hailey disease with the possible role of tofacitinib: A case series","author":"Shao","year":"2026","journal-title":"Indian J Dermatol Venereol Leprol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1935043\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:31:57Z","timestamp":1789536717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1935043\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2026.1935043"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1935043","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1935043"}}